15 November 2019 in The Journal of Immunology
The inflammasomes play critical roles in numerous pathological conditions largely through IL-1β and/or IL-18. However, additional effectors have been implied from multiple studies. In this study, through two independent mass spectrometry–based secretome screening approaches, we identified galectin-3 as an effector protein of the NLRP3 inflammasome. Although the activation of AIM2 or NLRC4 inflammasome also led to galectin-3 secretion, only the NLRP3 inflammasome controlled the serum galectin-3 level under physiological condition. Mechanistically, active gasdermin D drove the nonexosomal secretion of galectin-3 through the plasma membrane pores. In vivo, high-fat diet–fed Nlrp3−/− mice exhibited decreased circulating galectin-3 compared with wild-type animals. Of note, the improved insulin sensitivity in such Nlrp3−/− mice was aggravated by infusion of recombinant galectin-3. Moreover, galectin-3 was essential for insulin resistance induction in mice harboring the hyperactive Nlrp3A350V allele. Thus, the inflammasome–galectin-3 axis has been demonstrated as a promising target to intervene inflammasome and/or galectin-3 related diseases. Key Points Galectin-3 is discovered to be an inflammasome effector desensitizing insulin signaling. GSDMD perforates the plasma membrane for nonexosomal secretion of galectin-3. The inflammasome–galectin-3 axis exacerbates insulin resistance in vivo.
9 January 2023 in Endocrinology
The function of a hormone receptor requires mechanisms to control precisely where, when and at what level the receptor gene is expressed. An intriguing case concerns the selective induction of thyroid hormone receptor β2 (TRβ2), encoded by Thrb, in the pituitary and in cone photoreceptors in which it critically regulates expression of the opsin photopigments that mediate color vision. Here, we investigate the physiological significance of a candidate enhancer for induction of TRβ2 by mutagenesis of a conserved intron region in its natural context in the endogenous Thrb gene in mice. Mutation of e-box sites for bHLH (basic-helix-loop-helix) transcription factors preferentially impairs TRβ2 expression in cones whereas mutation of nearby sequences preferentially impairs expression in pituitary. A deletion encompassing all sites impairs expression in both tissues, indicating bifunctional activity. In cones, the e-box mutations disrupt chromatin acetylation, blunt the developmental induction of TRβ2 and ultimately, impair cone opsin expression and sensitivity to longer wavelengths of light. These results demonstrate the necessity of studying an enhancer in its natural chromosomal context for defining biological relevance and reveal surprisingly critical nuances of level and timing of enhancer function. Our findings illustrate the influence of non-coding sequences over thyroid hormone functions.
23 August 2026 in bioRxiv
Inflammatory hemophagocytes (iHPCs) differentiate from Ly6C HI monocytes, phagocytose red blood cells, and promote anemia and thrombocytopenia in a model of TLR7-driven macrophage activation syndrome (MAS), a life-threatening disorder. We identify IRF5 as a required and pharmacologically targetable driver of iHPC differentiation and MAS pathogenesis. Ly6C HI monocyte-to-iHPC differentiation in TLR7.1 mice involved extensive transcriptome and chromatin remodeling. Gene programs gained in iHPCs were enriched for genes near accessible IRF5-binding regions that also carried NF-κB, ETS, and AP-1 motifs, suggesting collaborative regulation. IRF5 was required in vitro for TLR7-induced upregulation of a subset of these genes. Cell-intrinsic IRF5 expression was required for iHPC differentiation but dispensable for TLR7.1 Ly6C HI monocytes and their transcriptional programs. Constitutive and myeloid-specific Irf5 deletion, as well as a small-molecule IRF5 inhibitor, reduced iHPCs and ameliorated MAS and lupus features. IRF5 is therefore a broad regulator of iHPC differentiation and a tractable target in TLR7-driven inflammation. SUMMARY: In TLR7-driven MAS, specialized monocyte-derived inflammatory hemophagocytes promote disease. Thulin, Lu et al. show that myeloid cell IRF5 is required for iHPC differentiation and MAS, and that IRF5 likely partners with other transcription factors, including NF-κB, to shape iHPCs programs.